カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界のがん用PARP阻害剤市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global PARP Inhibitors for Cancer Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19515）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19515
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：93
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界のがん用PARP阻害剤市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

がん用PARP阻害剤市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のがん用PARP阻害剤の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

がん用PARP阻害剤市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・リムパーザ、ゼジュラ、ルブラカ、タルゼナ、その他

用途別セグメントは次のように区分されます。
・卵巣がん、乳がん、その他

世界のがん用PARP阻害剤市場の主要な市場プレーヤーは以下のとおりです。
・AstraZeneca、Tesaro、Merck & Co、Clovis Oncology、Pfizer

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、がん用PARP阻害剤製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要ながん用PARP阻害剤メーカーの企業概要、2019年～2022年までのがん用PARP阻害剤の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要ながん用PARP阻害剤メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別がん用PARP阻害剤の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのがん用PARP阻害剤の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのがん用PARP阻害剤市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびがん用PARP阻害剤の産業チェーンを掲載しています。
・第13、14、15章では、がん用PARP阻害剤の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- がん用PARP阻害剤の概要
- 種類別分析（2017年vs2021年vs2028年）：リムパーザ、ゼジュラ、ルブラカ、タルゼナ、その他
- 用途別分析（2017年vs2021年vs2028年）：卵巣がん、乳がん、その他
- 世界のがん用PARP阻害剤市場規模・予測
- 世界のがん用PARP阻害剤生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- AstraZeneca、Tesaro、Merck & Co、Clovis Oncology、Pfizer
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：リムパーザ、ゼジュラ、ルブラカ、タルゼナ、その他
・用途別分析2017年-2028年：卵巣がん、乳がん、その他
・がん用PARP阻害剤の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・がん用PARP阻害剤のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・がん用PARP阻害剤のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・がん用PARP阻害剤の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・がん用PARP阻害剤の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The PARP Inhibitors for Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global PARP Inhibitors for Cancer market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Ovarian Cancer accounting for % of the PARP Inhibitors for Cancer global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Lynparza segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of PARP Inhibitors for Cancer include AstraZeneca, Tesaro, Merck & Co, Clovis Oncology, and Pfizer, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
PARP Inhibitors for Cancer market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Lynparza
Zejula
Rubraca
Talzenna
Other
Market segment by Application can be divided into
Ovarian Cancer
Breast Cancer
Other
The key market players for global PARP Inhibitors for Cancer market are listed below:
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe PARP Inhibitors for Cancer product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of PARP Inhibitors for Cancer, with price, sales, revenue and global market share of PARP Inhibitors for Cancer from 2019 to 2022.
Chapter 3, the PARP Inhibitors for Cancer competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PARP Inhibitors for Cancer breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and PARP Inhibitors for Cancer market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of PARP Inhibitors for Cancer.
Chapter 13, 14, and 15, to describe PARP Inhibitors for Cancer sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 PARP Inhibitors for Cancer Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global PARP Inhibitors for Cancer Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Lynparza
1.2.3 Zejula
1.2.4 Rubraca
1.2.5 Talzenna
1.2.6 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global PARP Inhibitors for Cancer Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Other
1.4 Global PARP Inhibitors for Cancer Market Size & Forecast
1.4.1 Global PARP Inhibitors for Cancer Sales in Value (2017 & 2021 & 2028)
1.4.2 Global PARP Inhibitors for Cancer Sales in Volume (2017-2028)
1.4.3 Global PARP Inhibitors for Cancer Price (2017-2028)
1.5 Global PARP Inhibitors for Cancer Production Capacity Analysis
1.5.1 Global PARP Inhibitors for Cancer Total Production Capacity (2017-2028)
1.5.2 Global PARP Inhibitors for Cancer Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 PARP Inhibitors for Cancer Market Drivers
1.6.2 PARP Inhibitors for Cancer Market Restraints
1.6.3 PARP Inhibitors for Cancer Trends Analysis
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca PARP Inhibitors for Cancer Product and Services
2.1.4 AstraZeneca PARP Inhibitors for Cancer Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Tesaro
2.2.1 Tesaro Details
2.2.2 Tesaro Major Business
2.2.3 Tesaro PARP Inhibitors for Cancer Product and Services
2.2.4 Tesaro PARP Inhibitors for Cancer Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Merck & Co
2.3.1 Merck & Co Details
2.3.2 Merck & Co Major Business
2.3.3 Merck & Co PARP Inhibitors for Cancer Product and Services
2.3.4 Merck & Co PARP Inhibitors for Cancer Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Clovis Oncology
2.4.1 Clovis Oncology Details
2.4.2 Clovis Oncology Major Business
2.4.3 Clovis Oncology PARP Inhibitors for Cancer Product and Services
2.4.4 Clovis Oncology PARP Inhibitors for Cancer Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer PARP Inhibitors for Cancer Product and Services
2.5.4 Pfizer PARP Inhibitors for Cancer Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 PARP Inhibitors for Cancer Breakdown Data by Manufacturer
3.1 Global PARP Inhibitors for Cancer Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global PARP Inhibitors for Cancer Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in PARP Inhibitors for Cancer
3.4 Market Concentration Rate
3.4.1 Top 3 PARP Inhibitors for Cancer Manufacturer Market Share in 2021
3.4.2 Top 6 PARP Inhibitors for Cancer Manufacturer Market Share in 2021
3.5 Global PARP Inhibitors for Cancer Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and PARP Inhibitors for Cancer Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global PARP Inhibitors for Cancer Market Size by Region
4.1.1 Global PARP Inhibitors for Cancer Sales in Volume by Region (2017-2028)
4.1.2 Global PARP Inhibitors for Cancer Revenue by Region (2017-2028)
4.2 North America PARP Inhibitors for Cancer Revenue (2017-2028)
4.3 Europe PARP Inhibitors for Cancer Revenue (2017-2028)
4.4 Asia-Pacific PARP Inhibitors for Cancer Revenue (2017-2028)
4.5 South America PARP Inhibitors for Cancer Revenue (2017-2028)
4.6 Middle East and Africa PARP Inhibitors for Cancer Revenue (2017-2028)
5 Market Segment by Type
5.1 Global PARP Inhibitors for Cancer Sales in Volume by Type (2017-2028)
5.2 Global PARP Inhibitors for Cancer Revenue by Type (2017-2028)
5.3 Global PARP Inhibitors for Cancer Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global PARP Inhibitors for Cancer Sales in Volume by Application (2017-2028)
6.2 Global PARP Inhibitors for Cancer Revenue by Application (2017-2028)
6.3 Global PARP Inhibitors for Cancer Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America PARP Inhibitors for Cancer Sales by Type (2017-2028)
7.2 North America PARP Inhibitors for Cancer Sales by Application (2017-2028)
7.3 North America PARP Inhibitors for Cancer Market Size by Country
7.3.1 North America PARP Inhibitors for Cancer Sales in Volume by Country (2017-2028)
7.3.2 North America PARP Inhibitors for Cancer Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe PARP Inhibitors for Cancer Sales by Type (2017-2028)
8.2 Europe PARP Inhibitors for Cancer Sales by Application (2017-2028)
8.3 Europe PARP Inhibitors for Cancer Market Size by Country
8.3.1 Europe PARP Inhibitors for Cancer Sales in Volume by Country (2017-2028)
8.3.2 Europe PARP Inhibitors for Cancer Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific PARP Inhibitors for Cancer Sales by Type (2017-2028)
9.2 Asia-Pacific PARP Inhibitors for Cancer Sales by Application (2017-2028)
9.3 Asia-Pacific PARP Inhibitors for Cancer Market Size by Region
9.3.1 Asia-Pacific PARP Inhibitors for Cancer Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific PARP Inhibitors for Cancer Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America PARP Inhibitors for Cancer Sales by Type (2017-2028)
10.2 South America PARP Inhibitors for Cancer Sales by Application (2017-2028)
10.3 South America PARP Inhibitors for Cancer Market Size by Country
10.3.1 South America PARP Inhibitors for Cancer Sales in Volume by Country (2017-2028)
10.3.2 South America PARP Inhibitors for Cancer Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa PARP Inhibitors for Cancer Sales by Type (2017-2028)
11.2 Middle East & Africa PARP Inhibitors for Cancer Sales by Application (2017-2028)
11.3 Middle East & Africa PARP Inhibitors for Cancer Market Size by Country
11.3.1 Middle East & Africa PARP Inhibitors for Cancer Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa PARP Inhibitors for Cancer Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of PARP Inhibitors for Cancer and Key Manufacturers
12.2 Manufacturing Costs Percentage of PARP Inhibitors for Cancer
12.3 PARP Inhibitors for Cancer Production Process
12.4 PARP Inhibitors for Cancer Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 PARP Inhibitors for Cancer Typical Distributors
13.3 PARP Inhibitors for Cancer Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global PARP Inhibitors for Cancer Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global PARP Inhibitors for Cancer Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 4. AstraZeneca Major Business
Table 5. AstraZeneca PARP Inhibitors for Cancer Product and Services
Table 6. AstraZeneca PARP Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Tesaro Basic Information, Manufacturing Base and Competitors
Table 8. Tesaro Major Business
Table 9. Tesaro PARP Inhibitors for Cancer Product and Services
Table 10. Tesaro PARP Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Merck & Co Basic Information, Manufacturing Base and Competitors
Table 12. Merck & Co Major Business
Table 13. Merck & Co PARP Inhibitors for Cancer Product and Services
Table 14. Merck & Co PARP Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Clovis Oncology Basic Information, Manufacturing Base and Competitors
Table 16. Clovis Oncology Major Business
Table 17. Clovis Oncology PARP Inhibitors for Cancer Product and Services
Table 18. Clovis Oncology PARP Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Pfizer Basic Information, Manufacturing Base and Competitors
Table 20. Pfizer Major Business
Table 21. Pfizer PARP Inhibitors for Cancer Product and Services
Table 22. Pfizer PARP Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Global PARP Inhibitors for Cancer Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 24. Global PARP Inhibitors for Cancer Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 25. Market Position of Manufacturers in PARP Inhibitors for Cancer, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 26. Global PARP Inhibitors for Cancer Production Capacity by Company, (K Units): 2020 VS 2021
Table 27. Head Office and PARP Inhibitors for Cancer Production Site of Key Manufacturer
Table 28. PARP Inhibitors for Cancer New Entrant and Capacity Expansion Plans
Table 29. PARP Inhibitors for Cancer Mergers & Acquisitions in the Past Five Years
Table 30. Global PARP Inhibitors for Cancer Sales by Region (2017-2022) & (K Units)
Table 31. Global PARP Inhibitors for Cancer Sales by Region (2023-2028) & (K Units)
Table 32. Global PARP Inhibitors for Cancer Revenue by Region (2017-2022) & (USD Million)
Table 33. Global PARP Inhibitors for Cancer Revenue by Region (2023-2028) & (USD Million)
Table 34. Global PARP Inhibitors for Cancer Sales by Type (2017-2022) & (K Units)
Table 35. Global PARP Inhibitors for Cancer Sales by Type (2023-2028) & (K Units)
Table 36. Global PARP Inhibitors for Cancer Revenue by Type (2017-2022) & (USD Million)
Table 37. Global PARP Inhibitors for Cancer Revenue by Type (2023-2028) & (USD Million)
Table 38. Global PARP Inhibitors for Cancer Price by Type (2017-2022) & (US$/Unit)
Table 39. Global PARP Inhibitors for Cancer Price by Type (2023-2028) & (US$/Unit)
Table 40. Global PARP Inhibitors for Cancer Sales by Application (2017-2022) & (K Units)
Table 41. Global PARP Inhibitors for Cancer Sales by Application (2023-2028) & (K Units)
Table 42. Global PARP Inhibitors for Cancer Revenue by Application (2017-2022) & (USD Million)
Table 43. Global PARP Inhibitors for Cancer Revenue by Application (2023-2028) & (USD Million)
Table 44. Global PARP Inhibitors for Cancer Price by Application (2017-2022) & (US$/Unit)
Table 45. Global PARP Inhibitors for Cancer Price by Application (2023-2028) & (US$/Unit)
Table 46. North America PARP Inhibitors for Cancer Sales by Country (2017-2022) & (K Units)
Table 47. North America PARP Inhibitors for Cancer Sales by Country (2023-2028) & (K Units)
Table 48. North America PARP Inhibitors for Cancer Revenue by Country (2017-2022) & (USD Million)
Table 49. North America PARP Inhibitors for Cancer Revenue by Country (2023-2028) & (USD Million)
Table 50. North America PARP Inhibitors for Cancer Sales by Type (2017-2022) & (K Units)
Table 51. North America PARP Inhibitors for Cancer Sales by Type (2023-2028) & (K Units)
Table 52. North America PARP Inhibitors for Cancer Sales by Application (2017-2022) & (K Units)
Table 53. North America PARP Inhibitors for Cancer Sales by Application (2023-2028) & (K Units)
Table 54. Europe PARP Inhibitors for Cancer Sales by Country (2017-2022) & (K Units)
Table 55. Europe PARP Inhibitors for Cancer Sales by Country (2023-2028) & (K Units)
Table 56. Europe PARP Inhibitors for Cancer Revenue by Country (2017-2022) & (USD Million)
Table 57. Europe PARP Inhibitors for Cancer Revenue by Country (2023-2028) & (USD Million)
Table 58. Europe PARP Inhibitors for Cancer Sales by Type (2017-2022) & (K Units)
Table 59. Europe PARP Inhibitors for Cancer Sales by Type (2023-2028) & (K Units)
Table 60. Europe PARP Inhibitors for Cancer Sales by Application (2017-2022) & (K Units)
Table 61. Europe PARP Inhibitors for Cancer Sales by Application (2023-2028) & (K Units)
Table 62. Asia-Pacific PARP Inhibitors for Cancer Sales by Region (2017-2022) & (K Units)
Table 63. Asia-Pacific PARP Inhibitors for Cancer Sales by Region (2023-2028) & (K Units)
Table 64. Asia-Pacific PARP Inhibitors for Cancer Revenue by Region (2017-2022) & (USD Million)
Table 65. Asia-Pacific PARP Inhibitors for Cancer Revenue by Region (2023-2028) & (USD Million)
Table 66. Asia-Pacific PARP Inhibitors for Cancer Sales by Type (2017-2022) & (K Units)
Table 67. Asia-Pacific PARP Inhibitors for Cancer Sales by Type (2023-2028) & (K Units)
Table 68. Asia-Pacific PARP Inhibitors for Cancer Sales by Application (2017-2022) & (K Units)
Table 69. Asia-Pacific PARP Inhibitors for Cancer Sales by Application (2023-2028) & (K Units)
Table 70. South America PARP Inhibitors for Cancer Sales by Country (2017-2022) & (K Units)
Table 71. South America PARP Inhibitors for Cancer Sales by Country (2023-2028) & (K Units)
Table 72. South America PARP Inhibitors for Cancer Revenue by Country (2017-2022) & (USD Million)
Table 73. South America PARP Inhibitors for Cancer Revenue by Country (2023-2028) & (USD Million)
Table 74. South America PARP Inhibitors for Cancer Sales by Type (2017-2022) & (K Units)
Table 75. South America PARP Inhibitors for Cancer Sales by Type (2023-2028) & (K Units)
Table 76. South America PARP Inhibitors for Cancer Sales by Application (2017-2022) & (K Units)
Table 77. South America PARP Inhibitors for Cancer Sales by Application (2023-2028) & (K Units)
Table 78. Middle East & Africa PARP Inhibitors for Cancer Sales by Region (2017-2022) & (K Units)
Table 79. Middle East & Africa PARP Inhibitors for Cancer Sales by Region (2023-2028) & (K Units)
Table 80. Middle East & Africa PARP Inhibitors for Cancer Revenue by Region (2017-2022) & (USD Million)
Table 81. Middle East & Africa PARP Inhibitors for Cancer Revenue by Region (2023-2028) & (USD Million)
Table 82. Middle East & Africa PARP Inhibitors for Cancer Sales by Type (2017-2022) & (K Units)
Table 83. Middle East & Africa PARP Inhibitors for Cancer Sales by Type (2023-2028) & (K Units)
Table 84. Middle East & Africa PARP Inhibitors for Cancer Sales by Application (2017-2022) & (K Units)
Table 85. Middle East & Africa PARP Inhibitors for Cancer Sales by Application (2023-2028) & (K Units)
Table 86. PARP Inhibitors for Cancer Raw Material
Table 87. Key Manufacturers of PARP Inhibitors for Cancer Raw Materials
Table 88. Direct Channel Pros & Cons
Table 89. Indirect Channel Pros & Cons
Table 90. PARP Inhibitors for Cancer Typical Distributors
Table 91. PARP Inhibitors for Cancer Typical Customers
List of Figures
Figure 1. PARP Inhibitors for Cancer Picture
Figure 2. Global PARP Inhibitors for Cancer Revenue Market Share by Type in 2021
Figure 3. Lynparza
Figure 4. Zejula
Figure 5. Rubraca
Figure 6. Talzenna
Figure 7. Other
Figure 8. Global PARP Inhibitors for Cancer Revenue Market Share by Application in 2021
Figure 9. Ovarian Cancer
Figure 10. Breast Cancer
Figure 11. Other
Figure 12. Global PARP Inhibitors for Cancer Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 13. Global PARP Inhibitors for Cancer Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global PARP Inhibitors for Cancer Sales (2017-2028) & (K Units)
Figure 15. Global PARP Inhibitors for Cancer Price (2017-2028) & (US$/Unit)
Figure 16. Global PARP Inhibitors for Cancer Production Capacity (2017-2028) & (K Units)
Figure 17. Global PARP Inhibitors for Cancer Production Capacity by Geographic Region: 2022 VS 2028
Figure 18. PARP Inhibitors for Cancer Market Drivers
Figure 19. PARP Inhibitors for Cancer Market Restraints
Figure 20. PARP Inhibitors for Cancer Market Trends
Figure 21. Global PARP Inhibitors for Cancer Sales Market Share by Manufacturer in 2021
Figure 22. Global PARP Inhibitors for Cancer Revenue Market Share by Manufacturer in 2021
Figure 23. PARP Inhibitors for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 24. Top 3 PARP Inhibitors for Cancer Manufacturer (Revenue) Market Share in 2021
Figure 25. Top 6 PARP Inhibitors for Cancer Manufacturer (Revenue) Market Share in 2021
Figure 26. Global PARP Inhibitors for Cancer Sales Market Share by Region (2017-2028)
Figure 27. Global PARP Inhibitors for Cancer Revenue Market Share by Region (2017-2028)
Figure 28. North America PARP Inhibitors for Cancer Revenue (2017-2028) & (USD Million)
Figure 29. Europe PARP Inhibitors for Cancer Revenue (2017-2028) & (USD Million)
Figure 30. Asia-Pacific PARP Inhibitors for Cancer Revenue (2017-2028) & (USD Million)
Figure 31. South America PARP Inhibitors for Cancer Revenue (2017-2028) & (USD Million)
Figure 32. Middle East & Africa PARP Inhibitors for Cancer Revenue (2017-2028) & (USD Million)
Figure 33. Global PARP Inhibitors for Cancer Sales Market Share by Type (2017-2028)
Figure 34. Global PARP Inhibitors for Cancer Revenue Market Share by Type (2017-2028)
Figure 35. Global PARP Inhibitors for Cancer Price by Type (2017-2028) & (US$/Unit)
Figure 36. Global PARP Inhibitors for Cancer Sales Market Share by Application (2017-2028)
Figure 37. Global PARP Inhibitors for Cancer Revenue Market Share by Application (2017-2028)
Figure 38. Global PARP Inhibitors for Cancer Price by Application (2017-2028) & (US$/Unit)
Figure 39. North America PARP Inhibitors for Cancer Sales Market Share by Type (2017-2028)
Figure 40. North America PARP Inhibitors for Cancer Sales Market Share by Application (2017-2028)
Figure 41. North America PARP Inhibitors for Cancer Sales Market Share by Country (2017-2028)
Figure 42. North America PARP Inhibitors for Cancer Revenue Market Share by Country (2017-2028)
Figure 43. United States PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Canada PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Mexico PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Europe PARP Inhibitors for Cancer Sales Market Share by Type (2017-2028)
Figure 47. Europe PARP Inhibitors for Cancer Sales Market Share by Application (2017-2028)
Figure 48. Europe PARP Inhibitors for Cancer Sales Market Share by Country (2017-2028)
Figure 49. Europe PARP Inhibitors for Cancer Revenue Market Share by Country (2017-2028)
Figure 50. Germany PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. France PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. United Kingdom PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Russia PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Italy PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Asia-Pacific PARP Inhibitors for Cancer Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific PARP Inhibitors for Cancer Sales Market Share by Application (2017-2028)
Figure 57. Asia-Pacific PARP Inhibitors for Cancer Sales Market Share by Region (2017-2028)
Figure 58. Asia-Pacific PARP Inhibitors for Cancer Revenue Market Share by Region (2017-2028)
Figure 59. China PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Korea PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America PARP Inhibitors for Cancer Sales Market Share by Type (2017-2028)
Figure 66. South America PARP Inhibitors for Cancer Sales Market Share by Application (2017-2028)
Figure 67. South America PARP Inhibitors for Cancer Sales Market Share by Country (2017-2028)
Figure 68. South America PARP Inhibitors for Cancer Revenue Market Share by Country (2017-2028)
Figure 69. Brazil PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East & Africa PARP Inhibitors for Cancer Sales Market Share by Type (2017-2028)
Figure 72. Middle East & Africa PARP Inhibitors for Cancer Sales Market Share by Application (2017-2028)
Figure 73. Middle East & Africa PARP Inhibitors for Cancer Sales Market Share by Region (2017-2028)
Figure 74. Middle East & Africa PARP Inhibitors for Cancer Revenue Market Share by Region (2017-2028)
Figure 75. Turkey PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Egypt PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Saudi Arabia PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. South Africa PARP Inhibitors for Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Manufacturing Cost Structure Analysis of PARP Inhibitors for Cancer in 2021
Figure 80. Manufacturing Process Analysis of PARP Inhibitors for Cancer
Figure 81. PARP Inhibitors for Cancer Industrial Chain
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
Figure 83. Methodology
Figure 84. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • IDO阻害剤のグローバル市場展望 2023年-2029年：二重IDO1/TDO阻害剤、共有IDO阻害剤
  • 世界の乳がん治療薬市場2022年：市場規模予測（～2028年）
  • イブルチニブBTK阻害剤のグローバル市場展望 2023年-2029年：タブレット、カプセル
  • 世界のPD-L1阻害剤市場2022年：市場規模予測（～2028年）
  • 直接的レニン阻害剤のグローバル市場展望 2023年-2029年：アリスキレン、レミキレン、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19515 )"世界のがん用PARP阻害剤市場2022年：市場規模予測（～2028年）" (英文：Global PARP Inhibitors for Cancer Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。